Hidden rebates mask true prices of pharmaceutical drugs in the market
Washington
COMPETITION can work in the pharmaceutical industry in counter-intuitive ways: New drugs typically enter the market with higher price tags than existing medications, and then all the prices rise. In the case of Gleevec, a breakthrough cancer drug approved in 2001, the advent of pricier and more potent competitors seemed to speed up the older drug's list price increases.
What remains frustratingly opaque, however, is precisely what the prices are. The drug industry commonly points out that list prices are essentially fiction; a drug's real price is a se…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Abbott beats quarterly profit estimates on strong medical device sales
Adidas shares surpass two-year high as 'terrace' sneaker trend boosts brand heat
LVMH’s first quarter sales growth slips to 3% on luxury slowdown
US Justice Department to file antitrust suit against Live Nation: WSJ
EU set to launch China probe on medical device procurement
Muji bets its minimalist retail will work for homes, hotels